Acrivon Therapeutics Q4 net loss narrows as expenses fall

Overview

• US biopharma firm's Q4 net loss narrowed from prior year as expenses declined

• Research and development and administrative costs fell, driven by fewer milestones and lower personnel costs

• Company expects cash and investments to fund operations into Q2 2027

Outlook

• Company expects cash and investments to fund operations into Q2 2027

• Acrivon plans to initiate Arm 4 of ACR-368 Phase 2b trial in H1 2026

• Company aims to complete enrollment for Arm 3 of ACR-368 trial in Q4 2026

Result Drivers

• CLINICAL TRIAL PRIORITIZATION - Co said lower R&D expenses were driven by prioritizing endometrial cancer in the ACR-368 clinical trial and fewer milestones scheduled

• LOWER PERSONNEL COSTS - General and administrative expenses declined due to a decrease in personnel costs, including non-cash stock compensation

Company press release: ID:nGNX7GkDs5

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Acrivon Therapeutics Inc is $10.50, about 540.2% above its March 18 closing price of $1.64

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.